Clin­i­cal tri­al starts slowed to be­low pre-pan­dem­ic lev­els last year, IQVIA analy­sis finds

Bio­phar­ma R&D spend­ing re­bound­ed in 2023, up $11 bil­lion from 2022 fol­low­ing a steep post-pan­dem­ic de­cline. But the num­ber of new clin­i­cal tri­al starts slowed to lev­els from be­fore the Covid-19 pan­dem­ic, the da­ta and ser­vices firm IQVIA said in a new re­port.

There are few­er pan­dem­ic-re­lat­ed tri­als, the analy­sis found, but al­so few­er of oth­er types of tri­als be­ing start­ed at both small and large bio­phar­ma com­pa­nies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.